Jones Trading Reiterates Buy Rating on Regulus Therapeutics (RGLS)

November 29, 2024 7:43 AM UTC Send to a Friend
Jones Trading analyst Catherine Novack reiterated a Buy rating and $8.00 price target on Regulus Therapeutics (NASDAQ: RGLS).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login